

# World Journal of *Gastrointestinal Oncology*

*World J Gastrointest Oncol* 2024 August 15; 16(8): 3368-3740



## EDITORIAL

- 3368 Remazolam combined with transversus abdominis plane block in gastrointestinal tumor surgery: Have we achieved better anesthetic effects?  
*Cao J, Luo XL, Lin Q*
- 3372 Immune-related gene characteristics: A new chapter in precision treatment of gastric cancer  
*Gao L, Lin Q*
- 3376 Navigating the labyrinth of long non-coding RNAs in colorectal cancer: From chemoresistance to autophagy  
*Yu JM, Sun CQ, Xu HH, Jiang YL, Jiang XY, Ni SQ, Zhao TY, Liu LX*
- 3382 Importance of early detection of esophageal cancer before the tumor progresses too much for effective treatment  
*Ono T*
- 3386 Early diagnosis of esophageal cancer: How to put “early detection” into effect?  
*Pubu S, Zhang JW, Yang J*
- 3393 Colon cancer screening: What to choose?  
*Gomez Zuleta MA*

## REVIEW

- 3397 Research progress on the development of hepatocyte growth factor/c-Met signaling pathway in gastric cancer: A review  
*Wei WJ, Hong YL, Deng Y, Wang GL, Qiu JT, Pan F*
- 3410 Research progress on the effect of pyroptosis on the occurrence, development, invasion and metastasis of colorectal cancer  
*Wang X, Yin QH, Wan LL, Sun RL, Wang G, Gu JF, Tang DC*

## MINIREVIEWS

- 3428 Importance of diet and intestinal microbiota in the prevention of colorectal cancer - colonoscopy early screening diagnosis  
*Jovandaric MZ*

## ORIGINAL ARTICLE

## Retrospective Cohort Study

- 3436 Analysis of vascular thrombus and clinicopathological factors in prognosis of gastric cancer: A retrospective cohort study  
*Chen GY, Ren P, Gao Z, Yang HM, Jiao Y*

- 3445** Application of fecal immunochemical test in colorectal cancer screening: A community-based, cross-sectional study in average-risk individuals in Hainan

*Zeng F, Zhang DY, Chen SJ, Chen RX, Chen C, Huang SM, Li D, Zhang XD, Chen JJ, Mo CY, Gao L, Zeng JT, Xiong JX, Chen Z, Bai FH*

- 3457** Effect of perioperative chemotherapy on resection of isolated pulmonary metastases from colorectal cancer: A single center experience

*Gao Z, Jin X, Wu YC, Zhang SJ, Wu SK, Wang X*

### Retrospective Study

- 3471** Microvascular structural changes in esophageal squamous cell carcinoma pathology according to intrapapillary capillary loop types under magnifying endoscopy

*Shu WY, Shi YY, Huang JT, Meng LM, Zhang HJ, Cui RL, Li Y, Ding SG*

- 3481** Camrelizumab, apatinib and hepatic artery infusion chemotherapy combined with microwave ablation for advanced hepatocellular carcinoma

*Zuo MX, An C, Cao YZ, Pan JY, Xie LP, Yang XJ, Li W, Wu PH*

- 3496** Serum ferritin and the risk of early-onset colorectal cancer

*Urback AL, Martens K, McMurphy HS, Chen EY, Citti C, Sharma A, Kardosh A, Shatzel JJ*

- 3507** Combining lymph node ratio to develop prognostic models for postoperative gastric neuroendocrine neoplasm patients

*Liu W, Wu HY, Lin JX, Qu ST, Gu YJ, Zhu JZ, Xu CF*

### Observational Study

- 3521** Efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer according to programmed cell death ligand 1

*Kang SW, Lim SH, Kim MJ, Lee J, Park YS, Lim HY, Kang WK, Kim ST*

- 3529** Endoscopic detection and diagnostic strategies for minute gastric cancer: A real-world observational study

*Ji XW, Lin J, Wang YT, Ruan JJ, Xu JH, Song K, Mao JS*

### Clinical and Translational Research

- 3539** Targeting colorectal cancer with Herba Patriniae and Coix seed: Network pharmacology, molecular docking, and *in vitro* validation

*Wang CL, Yang BW, Wang XY, Chen X, Li WD, Zhai HY, Wu Y, Cui MY, Wu JH, Meng QH, Zhang N*

### Basic Study

- 3559** Expression and significant roles of the long non-coding RNA CASC19/miR-491-5p/HMGA2 axis in the development of gastric cancer

*Zhang LX, Luo PQ, Wei ZJ, Xu AM, Guo T*

- 3585** Insulin-like growth factor 2 targets IGF1R signaling transduction to facilitate metastasis and imatinib resistance in gastrointestinal stromal tumors

*Li DG, Jiang JP, Chen FY, Wu W, Fu J, Wang GH, Li YB*

- 3600** Dysbiosis promotes recurrence of adenomatous polyps in the distal colorectum  
*Yin LL, Qi PQ, Hu YF, Fu XJ, He RS, Wang MM, Deng YJ, Xiong SY, Yu QW, Hu JP, Zhou L, Zhou ZB, Xiong Y, Deng H*
- 3624** Effect of acacetin on inhibition of apoptosis in *Helicobacter pylori*-infected gastric epithelial cell line  
*Yao QX, Li ZY, Kang HL, He X, Kang M*
- 3635** Curcumin for gastric cancer: Mechanism prediction *via* network pharmacology, docking, and *in vitro* experiments  
*Yang PH, Wei YN, Xiao BJ, Li SY, Li XL, Yang LJ, Pan HF, Chen GX*
- 3651** Lecithin-cholesterol acyltransferase is a potential tumor suppressor and predictive marker for hepatocellular carcinoma metastasis  
*Li Y, Jiang LN, Zhao BK, Li ML, Jiang YY, Liu YS, Liu SH, Zhu L, Ye X, Zhao JM*

### META-ANALYSIS

- 3672** Efficacy of hepatic arterial infusion chemotherapy and its combination strategies for advanced hepatocellular carcinoma: A network meta-analysis  
*Zhou SA, Zhou QM, Wu L, Chen ZH, Wu F, Chen ZR, Xu LQ, Gan BL, Jin HS, Shi N*

### SCIENTOMETRICS

- 3687** Current trends and hotspots of depressive disorders with colorectal cancer: A bibliometric and visual study  
*Yan ZW, Liu YN, Xu Q, Yuan Y*
- 3705** Research status and hotspots of tight junctions and colorectal cancer: A bibliometric and visualization analysis  
*Li HM, Liu Y, Hao MD, Liang XQ, Yuan DJ, Huang WB, Li WJ, Ding L*

### CASE REPORT

- 3716** Aggressive fibromatosis of the sigmoid colon: A case report  
*Yu PP, Liu XC, Yin L, Yin G*
- 3723** Jejunal sarcomatoid carcinoma: A case report and review of literature  
*Feng Q, Yu W, Feng JH, Huang Q, Xiao GX*

### LETTER TO THE EDITOR

- 3732** Current and future research directions in cellular metabolism of colorectal cancer: A bibliometric analysis  
*Jiang BW, Zhang XH, Ma R, Luan WY, Miao YD*
- 3738** Risk factors for the prognosis of colon cancer  
*Wu CY, Ye K*



**ABOUT COVER**

Editorial Board of *World Journal of Gastrointestinal Oncology*, Salem Youssef Mohamed, MD, Professor, Gastroenterology and Hepatology Unit, Department of Internal Medicine, Zagazig University, Zagazig 44516, Egypt. salemyousefmohamed@gmail.com

**AIMS AND SCOPE**

The primary aim of *World Journal of Gastrointestinal Oncology* (WJGO, *World J Gastrointest Oncol*) is to provide scholars and readers from various fields of gastrointestinal oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGO mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal oncology and covering a wide range of topics including liver cell adenoma, gastric neoplasms, appendiceal neoplasms, biliary tract neoplasms, hepatocellular carcinoma, pancreatic carcinoma, cecal neoplasms, colonic neoplasms, colorectal neoplasms, duodenal neoplasms, esophageal neoplasms, gallbladder neoplasms, *etc.*

**INDEXING/ABSTRACTING**

The WJGO is now abstracted and indexed in PubMed, PubMed Central, Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2024 edition of Journal Citation Reports® cites the 2023 journal impact factor (JIF) for WJGO as 2.5; JIF without journal self cites: 2.5; 5-year JIF: 2.8; JIF Rank: 71/143 in gastroenterology and hepatology; JIF Quartile: Q2; and 5-year JIF Quartile: Q2. The WJGO's CiteScore for 2023 is 4.2 and Scopus CiteScore rank 2023: Gastroenterology is 80/167; Oncology is 196/404.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: Si Zhao; Production Department Director: Xiang Li; Cover Editor: Jia-Ru Fan.

**NAME OF JOURNAL**

*World Journal of Gastrointestinal Oncology*

**ISSN**

ISSN 1948-5204 (online)

**LAUNCH DATE**

February 15, 2009

**FREQUENCY**

Monthly

**EDITORS-IN-CHIEF**

Monjur Ahmed, Florin Burada

**EDITORIAL BOARD MEMBERS**

<https://www.wjgnet.com/1948-5204/editorialboard.htm>

**PUBLICATION DATE**

August 15, 2024

**COPYRIGHT**

© 2024 Baishideng Publishing Group Inc

**INSTRUCTIONS TO AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjgnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjgnet.com/bpg/gerinfo/240>

**PUBLICATION ETHICS**

<https://www.wjgnet.com/bpg/GerInfo/288>

**PUBLICATION MISCONDUCT**

<https://www.wjgnet.com/bpg/gerinfo/208>

**ARTICLE PROCESSING CHARGE**

<https://www.wjgnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjgnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>



Clinical and Translational Research

## Targeting colorectal cancer with Herba Patriniae and Coix seed: Network pharmacology, molecular docking, and *in vitro* validation

Cheng-Lei Wang, Bing-Wei Yang, Xin-Yan Wang, Xue Chen, Wei-Dong Li, Hao-Yu Zhai, Ying Wu, Mu-Yao Cui, Jia-He Wu, Qing-Hui Meng, Nan Zhang

**Specialty type:** Medicine, research and experimental

**Provenance and peer review:**

Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review report's classification**

**Scientific Quality:** Grade C, Grade C

**Novelty:** Grade B, Grade B

**Creativity or Innovation:** Grade B, Grade B

**Scientific Significance:** Grade B, Grade B

**P-Reviewer:** Arumugam VA

**Received:** April 23, 2024

**Revised:** May 27, 2024

**Accepted:** June 17, 2024

**Published online:** August 15, 2024

**Processing time:** 106 Days and 13.7 Hours



**Cheng-Lei Wang, Bing-Wei Yang, Xin-Yan Wang, Xue Chen, Wei-Dong Li, Hao-Yu Zhai, Mu-Yao Cui, Jia-He Wu,** Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China

**Cheng-Lei Wang, Ying Wu,** The First Clinical Medical College, Shaanxi University of Chinese Medicine, Xianyang 712046, Shaanxi Province, China

**Wei-Dong Li,** Department of Scientific Research Management, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China

**Qing-Hui Meng,** School of Clinical Medicine Qinghai University, Xining 810000, Qinghai Province, China

**Nan Zhang,** School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100029, China

**Co-first authors:** Cheng-Lei Wang and Bing-Wei Yang.

**Corresponding author:** Wei-Dong Li, MD, Chief Doctor, Department of Scientific Research Management, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, No. 5 Beixiangge, Xicheng District, Beijing 100053, China. [liweidongdoctor@hotmail.com](mailto:liweidongdoctor@hotmail.com)

### Abstract

#### BACKGROUND

Herba Patriniae and Coix seed (HC) constitute a widely utilized drug combination in the clinical management of colorectal cancer (CRC) that is known for its diuretic, anti-inflammatory, and swelling-reducing properties. Although its efficacy has been demonstrated in a clinical setting, the active compounds and their mechanisms of action in CRC treatment remain to be fully elucidated.

#### AIM

To identify the active, CRC-targeting components of HC and to elucidate the mechanisms of action involved.

#### METHODS

Active HC components were identified and screened using databases. Targets for each component were predicted. CRC-related targets were obtained from human

gene databases. Interaction targets between HC and CRC were identified. A “drug-ingredient-target” network was created to identify the core components and targets involved. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were conducted to elucidate the key pathways involved. Molecular docking between core targets and key components was executed. *In vitro* experiments validated core monomers.

## RESULTS

Nineteen active components of HC were identified, with acacetin as the primary active compound. The predictive analysis identified 454 targets of the active compounds in HC. Intersection mapping with 2685 CRC-related targets yielded 171 intervention targets, including 30 core targets. GO and KEGG analyses indicated that HC may influence the phosphoinositide 3-kinase (PI3K)/Akt signaling pathway. Molecular docking showed that acacetin exhibited an optimal interaction with *AKT1*, identifying *PI3K*, *AKT*, and *P53* as key genes likely targeted by HC during CRC treatment. Acacetin inhibited HT-29 cell proliferation and migration, as well as promoted apoptosis, *in vitro*. Western blotting analysis revealed increased *p53* and cleaved caspase-3 expression and decreased levels of *p-PI3K*, *p-Akt*, and survivin, which likely contributed to CRC apoptosis.

## CONCLUSION

Acacetin, the principal active compound in the HC pair, inhibited the proliferation and migration of HT-29 cells and promoted apoptosis through the PI3K/Akt/p53 signaling pathway.

**Key Words:** Colorectal cancer; Baijiangcao (Herba Patriniae); Yiyiren (Coix seed); Acacetin; Proliferation; Migration; Apoptosis; Network pharmacology

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** We identified acacetin as the key active ingredient of “Herba Patriniae and Coix seed.” Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses suggested that “Herba Patriniae and Coix seed” acts on colorectal cancer (CRC) through the phosphoinositide 3-kinase (PI3K)/Akt signaling pathway, and molecular docking showed that the best docking effect was between acacetin and *AKT1*. *In vitro* experiment results corroborated that acacetin inhibits the proliferation and migration, and promotes apoptosis of CRC cells through the PI3K/Akt/p53 signaling pathway.

**Citation:** Wang CL, Yang BW, Wang XY, Chen X, Li WD, Zhai HY, Wu Y, Cui MY, Wu JH, Meng QH, Zhang N. Targeting colorectal cancer with Herba Patriniae and Coix seed: Network pharmacology, molecular docking, and *in vitro* validation. *World J Gastrointest Oncol* 2024; 16(8): 3539-3558

**URL:** <https://www.wjgnet.com/1948-5204/full/v16/i8/3539.htm>

**DOI:** <https://dx.doi.org/10.4251/wjgo.v16.i8.3539>

## INTRODUCTION

Colorectal cancer (CRC) is the third most frequently diagnosed cancer worldwide and accounts for approximately 10% of all cancer cases. Additionally, it is the second leading cause of cancer-related deaths worldwide, emphasizing its significant impact on global health[1]. The incidence of CRC is rising annually, with the age of onset decreasing, and mortality from recurrence and metastasis remaining a significant challenge[2]. The etiology of CRC is multifaceted and closely associated with various factors, such as age, sex, lifestyle, obesity, smoking, and dietary habits[3]. Most CRCs are sporadic and undergo slow progression from adenocarcinoma to carcinoma. Approximately 10% of adenomatous polyps develop into adenocarcinoma, which is proportional to the polyp size. In addition, CRC is closely associated with familial and hereditary syndromes. People with a family history of CRC have an increased risk of disease, including those with genetic syndromes (for example, lynch syndrome or familial adenomatous polyposis)[4]. Some studies have found that patients with a history of inflammatory bowel disease are prone to metastasis, with reduced histological differentiation, and increased lymphovascular and perineural invasion when compared with patients with sporadic CRC[5]. Surgery complemented by radiotherapy, chemotherapy, and targeted therapy is the primary treatment option for CRC. Traditional Chinese medicine (TCM) plays a pivotal role in the prevention and treatment of CRC, particularly during various stages of comprehensive treatment[6]. TCM significantly mitigates adverse reactions from radiotherapy and chemotherapy, enhances disease immunity, improves patient quality of life and survival rates, and reduces tumor recurrence and metastasis rates[7]. A randomized controlled study of the Chinese herbal compound, PRM1201[8], indicated that adjunctive chemotherapy could extend progression-free survival post-CRC surgery. In a previous study conducted by Yang Yufei's team[9], a prospective cohort of 222 patients who underwent radical treatment for CRC was followed over a period of five years. The findings revealed that patients treated with Sijunzi Decoction and additional TCMs exhibited substantially lower rates of cancer recurrence and metastasis than those who received only conventional therapy (21.38% *vs* 38.18%). Furthermore, the average duration before the onset of recurrence and metastasis in patients

receiving the combination of Sijunzi Decoction and TCMs was significantly longer (26.5 months) compared to that in the group receiving conventional treatment (16.0 months). Notably, the median time delay from recurrence to metastasis in the combination treatment group was 10.5 months, and this group reported no instances of liver metastasis. A retrospective cohort study[10] demonstrated that TCM treatment has a positive impact on extending the median overall survival in patients with CRC (75 months *vs* 65 months).

TCM asserts that the core pathological factors of CRC include dampness, heat, deficiency, and blood stasis, with most of the pathological properties characterized by a damp-heat turbidity-stasis interaction. Furthermore, damp-heat accumulation is common in the pathogenesis of CRC. The invasion and accumulation of dampness and heat in the colon disrupt the smooth flow of qi and blood, leading to obstruction by heat stasis toxins in the intestines, which ultimately results in cancer. Core issues include deficiency syndrome, particularly in the spleen and kidneys, and intestinal weakness. Empirical evidence has primarily identified dampness-heat stasis toxin as the main pathological factor, with clinical treatments focusing on heat-clearing, dampness-removing, anticancer, and blood-activating drugs. Herba Patriniae and Coix seed (HC) is a widely utilized drug combination in the clinical management of CRC, offering diuretic, pus-clearing, blood-dispersing, and anti-inflammatory effects. *Patrinia* and Coix seeds constitute the primary components of the classical formulation of Yiyi Fuzi Baijiang powder (YFBP), initially documented in the Synopsis of the Golden Chamber by the outstanding Chinese medicine scholar, Zhang Zhongjing (Eastern Han Dynasty, 150-219 AD). This formulation comprises three TCM ingredients (Coix seed, aconite seed, and Herba Patriniae) blended in a ratio of 30:6:15. In the TCM field, this formulation has been traditionally used to treat gastrointestinal (GI) disorders. Previous research demonstrated that the clinical application of YFBP may enhance the quality of life of patients with CRC, and preliminary studies have shown promising results for its use in CRC treatment. Moreover, another study identified that YFBP effectively inhibits tumor growth by disrupting the phosphoinositide 3-kinase (PI3K)/Akt signaling pathway in CRC mouse models[11]. Further investigations demonstrated that YFBP significantly slowed CRC progression in *Apc<sup>Min/+</sup>* mice. This was achieved through modulation of the gut microbiota and a reduction in the production of regulatory T cells, offering a potential mechanism that explains its therapeutic effects[12]. The perennial herbs, *Patrinia scabiosifolia* Fisch and *P. illosa* Juss, were first documented in the Shennong Herbarium. These herbs are known for their ability to clear heat, detoxify, eliminate abscesses and pus, remove blood stasis, and relieve pain[13]. Flavonoids, triterpenoid saponins, iridoid terpenes, volatile oils, sterols, and phenylpropanoids (coumarins and lignans) are the primary active constituents extracted from *Patrinia*, with flavonoids and saponins identified as the key anti-tumor agents[14]. *Coix lachryma-jobi* has garnered significant attention owing to its wide range of biological activities. This herb, mainly planted in Asia and Africa, as well as the marginal areas of the Mediterranean, has the capacity to clear heat and dampness[15]. Coix seed comprises various bioactive components, including polysaccharides, proteins, polyphenols, oils, cinnamolactones, and sterols, among others. Notably, Coix seed oil (CSO) exhibits significant anticancer efficiency[16].

The bioactive components and mechanisms underlying the CRC inhibitory activity of HC remain unclear. Network pharmacology studies of TCM aim to explore the complex mechanisms of diseases, TCM syndromes, and herbal efficiency. It integrates systems biology, multi-pharmacology, and molecular networks. This approach provides a comprehensive description of the connections among the drug, related targets, and the disease, presented as a visual “active ingredient-target-disease” network[17]. Molecular docking is used to simulate the interactions between small molecules and proteins, and has seen considerable expansion in its application for investigating the mechanisms of action of new drugs in the last few years. Researchers have utilized a combination of network pharmacology, molecular docking, and experimental methods to investigate the active components, potential targets, and molecular mechanisms of HC in the treatment of CRC. These findings were preliminarily verified using cell-based experiments. The results indicated that acacetin is a key active component of HC, which exerts its anti-CRC function by suppressing tumor cell proliferation and promoting apoptosis *via* the PI3K/Akt/p53 signaling pathway. This study aimed to provide a series of references and an innovative foundation for the clinical applications and fundamental research on HC in CRC treatment.

## MATERIALS AND METHODS

### Network pharmacology analysis

**Identification of active compounds and forecasting of putative targets:** Using “patrinia” and “Coixen” as keywords, data were searched for on the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP; <https://old.tcm-sp-e.com/tcm-sp.php>). Retrieval criteria were set as oral bioavailability  $\geq 30\%$  and drug-likeness (DL)  $\geq 0.18$ [18]. Further screening was conducted *via* the Swiss ADME platform (<http://www.swissadme.ch>), selecting compounds with “high” GI absorption and DL affirmed by at least two “Yes” responses. This study screened for viable components in *Patrinia* and Coix seed. Active components were identified by retrieving their SMILES notation *via* PubChem (<https://pubchem.ncbi.nlm.nih.gov>) based on their unique identifiers. Chemical targets were predicted by integrating the data with the Swiss Target Prediction database (<http://www.swisstargetprediction.ch>). Target and duplicate data with a confidence value of 0 were excluded.

**Forecasting CRC-associated target genes:** Using “Colorectal Cancer” as a keyword, CRC targets were identified in the GeneCards (<https://www.genecards.org>) and OMIM (<https://www.omim.org>) databases, and further explored in the DisGeNET database (<https://www.disgenet.org>). The top 2000 targets were selected through median screening in Microsoft Excel. The genes identified from the three databases were aggregated, and the duplicates were removed[19].

**Construction of the HC-CRC protein-protein interaction network:** Using Venny 2.1.0 (<http://www.liuxiaoyuanyuan.cn>), intersection targets between CRC and HC were identified and imported into the STRING database (<https://www.string-db.org>).



[cn.string-db.org](https://cn.string-db.org)) to obtain protein-protein interaction (PPI) networks. The PPI network was analyzed using Cytoscape 3.9.1, with thresholds set for Closeness ( $> 0.003$ ), Betweenness ( $> 149.94$ ), and Degree ( $> 34.15$ ) to screen for core targets [20].

**Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses:** To identify intersecting targets, the DAVID database (<https://david.ncifcrf.gov>) was utilized for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. The filter condition was set with “Homo sapiens” as the species, and a significance threshold of  $P < 0.05$  was established. GO enrichment analysis yielded results for biological process (BP), cellular component (CC), and molecular function (MF). This included an analysis of the KEGG signaling pathways. The selection criteria focused on the smallest  $P$  values, prioritizing the top 10 GO terms and top 20 KEGG pathways for further analysis. These were then imported into a bioinformatics platform (<http://www.bioinformatics.com.cn>) for visual analysis [21].

**Integration of drug, component, target gene, pathway, and disease interaction networks:** Data comprising *Patrinia*-Coix seed active ingredients, HC-CRC intersection targets, pathways, and diseases were input into Cytoscape 3.9.1 for 3D network visualization. In this network, the active ingredients and targets were designated as nodes, whereas the edges represented the interactions between these nodes [22].

**Molecular docking:** Molecular docking was performed for the five target proteins with the highest Degree scores according to the PPI network, which corresponded to the five active ingredients with the most intersection targets. The 3D structures of the compounds and target proteins were downloaded from PubChem and processed using AutoDock Tools 1.5.6 for the removal of crystal water, addition of hydrogen atoms, identification of rotatable bonds, structural optimization, and energy minimization. The structures were saved in pdbqt format. Binding energy calculations were performed using AutoDock Vina 1.1.2, with docking results visualized using PyMOL 2.1, and LigPlot + 2.2.8 used for analyzing the interaction modes between compounds and target proteins. This analysis included the specifics of compound-protein residue interactions and hydrogen bonding effects. Subsequently, the binding affinities of the screened compounds for their targets were estimated based on their binding energies [23,24].


## Experimental verification

**Drugs and reagents:** A range of reagents and supplies were utilized in this study, including acacetin (lot number: 00017; Sigma-Aldrich, St. Louis, MO, United States) and RPMI-1640 medium (lot number: 10491; Solarbio, Beijing, China). Extra-grade fetal bovine serum was sourced from the Wuhan Puroxai Company (lot number: 164210; Wuhan, China), and antibiotics (penicillin-streptomycin double antibody) obtained from Gibco (lot number: 15140-122; Waltham, MA, United States). Cell culture and apoptosis detection kits, such as the Trypsin-EDTA (0.25%, lot number: 25200056; Gibco) and Annexin V-FITC Apoptosis Detection Kits (lot number: 556547; BD Biosciences, Franklin Lakes, NJ, United States), were used. Additionally, the key proteins, *PI3K*, *AKT*, and *P53*, as well as antibodies against them, were purchased from Abcam (with respective lot numbers: Ab151549, ab179463, and ab131442; Cambridge, United Kingdom). Phosphorylation status was assessed using phospho-*PI3* kinase p85/p55 (batch No. 4228; Cell Signaling Technology, Danvers, MA, United States) and phospho-*Akt* (Ser473) XP rabbit monoclonal (lot number: 4060; Cell Signaling Technology) antibodies. Apoptotic markers, including cleaved caspase-3 (lot number: 9661; Cell Signaling Technology) and survivin (lot number: 2808; Cell Signaling Technology), along with the secondary antibodies, anti-rabbit IgG (lot number: 7074P2; Cell Signaling Technology) and  $\beta$ -actin (lot number: AF7018; Affinity Biosciences, Zhenjiang, China), were also utilized in the analysis (Figure 1).

**Experimental instruments:** In this study, a variety of specialized laboratory equipment was utilized to ensure the precision of the experimental results. This included an optical inverted microscope from Nikon (model ECLIPSE Ts2R; Tokyo, Japan) for cell observation and a low-speed centrifuge from the Baiyang Centrifuge Factory (model B600-A) for sample preparation. Our laboratory also employed a Super Clean Table from the Beijing Changping Great Wall Air Purification Engineering Company (Beijing, China) for maintaining a contaminant-free environment, alongside a 37 °C and 5% CO<sub>2</sub> Constant Temperature Aseptic Incubator from Sanyo (model MCO-18AIC; Osaka, Japan) for cell culture. Cells were counted on Marienfeld plates (lot number: 0650030; Paul Marienfeld, Germany). Cell populations were analyzed using a flow cytometer (BD FACSCanto; BD Biosciences), and enzyme activity was measured using an enzyme marker from BioTek (Synergy HT; Winooski, VT, United States). Additionally, for sample centrifugation, a low-temperature and high-speed centrifuge from Sigma-Aldrich (model 3-18K/3K30) was used. Protein analysis was performed using a suite of equipment from Bio-Rad (Hercules, CA, United States), including a protein electrophoresis device, protein electrophoresis transfer device, and gel imaging system (GelDoc XR Bio-Rad).

**Cell culture:** HT-29 cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin. The cultures were maintained in a 5% CO<sub>2</sub> incubator at 37 °C. Upon reaching 80%-90% confluence, the cells were digested with 0.25% EDTA. Only cells in the growth phase were selected for subsequent experiments.

**Cell viability assay:** HT-29 cells were seeded into 96-well plates at a density of  $5 \times 10^4$  cells/well. After 24 hours of incubation, they were treated with various concentrations of acacetin (440.000, 220.000, 110.000, 55.000, 27.500, 13.750, 6.875, and 0  $\mu$ M). Additionally, blank (containing complete culture medium without cells) and control wells (containing cells in complete culture medium but without the drug) were established. After 24 and 48 hours of incubation, the medium was replaced with fresh medium containing a 10% cell counting kit-8 (CCK-8) solution, and the plates were



**Figure 1** Flow chart depicting the study methodology. Various databases were searched to obtain common targets of colorectal cancer (CRC) and Herba Patriniae-Coix seed. Possible targets and pathways for CRC were analyzed via network pharmacology and finally verified through *in vitro* experiments.

subsequently incubated for an additional 1 hour in the dark. The absorbance of each well was measured at 450 nm using an enzyme-linked immunosorbent assay reader. The cell survival rate was calculated using the following formula: Cell survival rate (%) = (Experimental group absorbance - Blank group absorbance) / (Control group absorbance - Blank group absorbance) × 100.

Based on the results, the optimal concentration of acacetin was determined for further experiments.

**Wound healing assay:** The migration of HT-29 cells was measured using a cell scratch assay. Cells were seeded in 6-well plates at a density of  $1 \times 10^6$  cells/well and cultured for 24 hours. Subsequently, a vertical scratch was made along the center of each well. The wells were then treated with various concentrations of acacetin. Photographs were taken at 0 hour, 24 hours, and 48 hours after wound-scratching. The scratch distance was quantified using ImageJ software, and the cell migration rate was assessed using the following formula: Cell migration rate (%) = (Initial distance - final distance) / initial distance × 100.

**Flow cytometry assay:** HT-29 cells were cultured in 6-well plates at a density of  $1 \times 10^6$  cells/well and incubated for 24 hours. Following treatment with various concentrations of acacetin for 24 hours, the cells were harvested and resuspended in  $1 \times$  Binding Buffer. To each tube, 5  $\mu$ L Annexin V-FITC and PI antibody were added, along with 100  $\mu$ L of the cell suspension. The mixture was then mixed gently. After incubation in a dark room at an appropriate temperature for 15 minutes, 400  $\mu$ L of  $1 \times$  Binding Buffer was added to the cells, which were then measured *via* flow cytometry for up to 1 hour.

**Western blotting analysis:** After treatment with varying concentrations of acacetin for 24 hours, the cells were harvested, lysed, and centrifuged to extract total protein. The protein concentration was quantified using a BCA protein detection kit. Proteins were denatured at 100 °C for 8 minutes. A 20  $\mu$ g protein sample was subjected to SDS-PAGE at 140 V for 1 hour, followed by 100 V post-electrophoresis. The samples were then cooled on ice for 1 hour before being transferred onto a polyvinylidene fluoride (PVDF) membrane. The membrane was blocked with 5% skim milk powder for 2 hours, followed by the addition of the primary antibody and overnight incubation at 4 °C. Subsequently, the primary antibody was removed, and the membrane was washed three times with  $1 \times$  PBST solution (5 minutes per wash). The secondary antibody was then incorporated and incubated at room temperature for 1 h, followed by removal and three washes with  $1 \times$  PBST solution. A 1:1 mixture of chemiluminescence kit A-B was applied to the PVDF membrane and incubated for 30 seconds. Target protein bands were imaged using a gel imaging system, and the grayscale values of each band were analyzed using Image Lab software. The grayscale ratios of cleaved caspase-3, survivin, *PI3K*, *p-PI3K*, *Akt*, *p-Akt*, *P53*, and  $\beta$ -actin were employed to quantify the relative protein expression levels in each group.

### Statistical analysis

All data were analyzed using IBM SPSS Statistics for Windows, version 25 (IBM Corp., Armonk, NY, United States), and GraphPad Prism, version 10.0 (GraphPad Software, La Jolla, CA, United States), and expressed as the mean  $\pm$  SD. One-way analysis of variance was used to assess differences between groups, with  $P \leq 0.05$  set to determine statistically significant differences.

## RESULTS

### Active compounds and putative targets of HC

Fifty-two active ingredients and 38 Coix seed variants were identified using the TCMSP platform. Utilizing the screening criteria of an oral bioavailability  $\geq 30\%$ , DL  $\geq 0.18$ , “high” GI absorption as per the Swiss ADME database, and at least two “Yes” responses for DL, 12 active ingredients were identified in *Patrinia* and seven in Coix seed. Nineteen active ingredients were ultimately screened, of which sitosterol (MOL000359) and stigmasterol (MOL000449) were common to both herbs. Canonical SMILES for these 19 compounds were retrieved from the PubChem database and input into the Swiss Target Prediction database. After eliminating targets with a confidence value of 0 and duplicate entries, 454 potential targets of the HC active ingredients were identified. The five compounds with the highest number of targets were acacetin, luteolin, quercetin, bolusanthol B, and sinoacutine. Table 1 shows information related to the active ingredients identified in HC.

### Potential CRC and HC intersection targets


From the GeneCards, DisGeNET, and OMIM databases, 1600, 1206, and 500 CRC targets were identified, respectively. By merging these lists and eliminating duplicate entries, a total of 2685 CRC-related targets were compiled. A Venn diagram (Figure 2) was used to illustrate the identification of 171 intersecting targets between HC and CRC.

### PPI network and hub targets analyses

To elucidate the relationships among the 171 intersecting target molecules, a PPI network was constructed using the STRING database and further visualized *via* Cytoscape 3.9.1 software (Figure 3), which consisted of 171 nodes and 2920 edges (Figure 3A). Following the 2.1.3 screening criteria, 30 nodes and 369 edges were identified (Figure 3B and C). The CentiScaPe 2.2 plugin was used to analyze the target set and isolate the core targets. Table 2 shows the top 10 core genes identified. Furthermore, alluvial diagrams were used to illustrate the relationships among the two herbs, eight core components, and nine core genes (Figure 3D). Node connectivity is depicted through variations in the sizes of the nodes

**Table 1 Basic information of the 19 active ingredients in Herba Patriniae-Coix seed**

Herb	Mol ID	Molecule name	Oral bioavailability (%)	Drug-likeness	Target amount
BJC1	MOL001676	Vilmorrianine C	33.96	0.22	59
BJC2	MOL001677	Asperglaucide	58.02	0.52	100
BJC3	MOL001678	Bolusanthol B	39.94	0.41	100
BJC4	MOL001689	Acacetin	34.97	0.24	100
BJC5	MOL002322	Isovitexin	31.29	0.72	3
BJC6	MOL001697	Sinoacutine	63.39	0.53	100
BJC7	MOL000358	Beta-sitosterol	36.91	0.75	44
BJC8	MOL000359	Sitosterol	36.91	0.75	44
BJC9	MOL000422	Kaempferol	41.88	0.24	3
BJC10	MOL000449	Stigmasterol	43.83	0.76	41
BJC11	MOL000006	Luteolin	36.16	0.25	100
BJC12	MOL000098	Quercetin	46.43	0.28	100
YYR1	MOL001323	Sitosterol alpha 1	43.28	0.78	60
YYR2	MOL001494	Mandenol	42.00	0.19	100
YYR3	MOL002882	[(2R)-2,3-dihydroxypropyl](Z)-octadec-9-enoate	34.13	0.30	41
YYR4	MOL000359	Sitosterol	36.91	0.75	44
YYR5	MOL000449	Stigmasterol	43.83	0.76	41
YYR6	MOL008121	2-Monoolein	34.23	0.29	52
YYR7	MOL000953	CLR	37.87	0.68	46

**Figure 2 Venn diagram of the active ingredients and disease targets.**


and edges, as well as through color intensity. Larger sizes and darker colors indicate stronger connections within the network.

### GO and KEGG pathway enrichment analyses


The key biological functions of HC for CRC treatment were elucidated through GO and KEGG enrichment analyses. GO analysis revealed that the numbers of CC, MF, and BP processes were 91, 149, and 614, respectively ( $P < 0.05$ ). Based on prior results, the top five CC processes comprised the plasma membrane, cytoplasm, cytosol, nucleus, and nucleoplasm. The top five MF processes included protein binding, ATP binding, protein serine/threonine/tyrosine kinase activity, identical protein binding, and enzyme binding. The first five BPs identified were signal transduction, protein phosphorylation, negative regulation of the apoptotic process, transcription from the RNA polymerase II promoter, and positive regulation of gene expression. The top 10 bar and bubble charts are illustrated in Figure 4. After KEGG enrichment analysis, 154 signaling pathways were identified ( $P < 0.05$ ). The top five signaling pathways identified included pathways in cancer, the *PI3K/Akt* signaling pathway, proteoglycans in cancer, chemical carcinogen-receptor activation, and microRNAs in cancer; HC can likely target CRC through these pathways. A bubble diagram of the first 20 bars is shown in Figure 5.




**A**




**B**



**C**





**Figure 3 Protein-protein interaction analysis of the intersection targets between Herba Patriniae-Coix seed and colorectal cancer.** A: The protein-protein interaction (PPI) network between the Herba Patriniae-Coix seed and colorectal cancer intersection targets; B and C: The top 30 core targets identified through PPI network analysis; D: The impact map revealing the relationship between traditional Chinese medicine, core components, and core genes.

### Construction of an herbal composition-target-pathway-disease network

Two herbs, 19 active ingredients, 171 cross targets, the top 10 pathways, and CRC diseases were integrated into Cytoscape 3.9.1 to establish an herbal ingredient-target-pathway-disease network (Figure 6). Upon examining the network, the network diagram was found to comprise 203 nodes and 893 edges. Acacetin exhibited the highest value, followed by luteolin, quercetin, bolusanthol B, and sinoacutine. The signaling pathway that exhibited the highest degree of involvement was the “PI3K-Akt signaling pathway.” Within a network, the degree value of a node depends on the number of edges connected to other nodes. Nodes with high degree values are often the key components of a network and play significant roles within it. Data pertaining to the major TCM components, signaling pathways, and targets are summarized in Tables 3, 4 and 5.


### Molecular docking study

Five key target proteins (EGFR, AKT1, TNF, HSP90AA1, and SRC) were molecularly docked with five core components (acacetin, luteolin, quercetin, bolusanthol B, and sinoacutine), and the binding capacities of target and ligand proteins evaluated. The AutoDock software predicted the binding capacities, with all binding energies being < -6.0 kcal/mol (Figure 7). All five active ingredients demonstrated strong binding affinities for EGFR, AKT1, TNF, HSP90AA1, and SRC. Among these, acacetin, bolusanthol B, luteolin, and quercetin exhibited the most effective docking with AKT1. Consequently, molecular docking with the human target protein, AKT1, was conducted using AutoDock Vina 1.1.2, and the results are presented in Table 6. The findings indicated that the four compounds exhibited a significant binding effect with AKT1, with binding energies < -6.0 kcal/mol. The complex resulting from the compound-protein docking was synthesized using PyMOL 2.1 software, from which the binding mode was derived. The LigPlot + 2.2.8 software elucidated the amino acid residues of the compound and the protein pocket, as detailed in Figure 8. For example, the amino acid residues of luteolin and quercetin that interacted with AKT1 included THR-211, TYR-272, and GLN-79. The interaction of acacetin and bolusanthol B with AKT1 involved amino acid residues THR-211, ASP-274, and THR-81, demonstrating a well-matched molecular and protein interface.

### Acacetin inhibits the proliferation of HT-29 cells

In this study, we examined the cytotoxicity and inhibitory effects of acacetin on HT-29 cells. Cell viability was measured using the CCK-8 assay after treatment with various concentrations of acacetin for 24 and 48 hours. Acacetin markedly inhibited HT-29 cell proliferation (Figure 9).






**Figure 4 Gene ontology.** A and B: Gene ontology functional enrichment analysis. BP: Biological process; CC: Cell component; MF: Molecular function.

**Table 2** Top 10 core targets in the protein-protein interaction network between Herba Patriniae-Coix seed and colorectal cancer

Rank	Target	Degree
1	EGFR	122
2	AKT1	122
3	TNF	109
4	HSP90AA1	105
5	SRC	102
6	HIF1A	99
7	ESR1	97
8	HSP90AB1	94
9	MMP9	90
10	MAPK3	87



**Figure 5** Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis. The X-axis denotes the enrichment rate of these genes within the total gene pool, whereas the Y-axis indicates the enrichment pathway of the target gene ( $P \leq 0.05$ ). The depth of the color corresponds to the magnitude of the value, whereas the size of the circle reflects the enrichment count of these pathways. The top five signaling pathways are: Pathways in cancer, phosphoinositide 3-kinase-Akt signaling pathway, proteoglycans in cancer, chemical carcinogenesis, receptor activation, and microRNAs in cancer.

### Acacetin inhibits HT-29 cell migration


Scratch assays were conducted on HT-29 cells that were treated with acacetin at concentrations of 0, 38, and 55  $\mu\text{M}$ . As shown in **Figure 10**, HT-29 cells in the experimental group exhibited negligible migration compared with those in the control group ( $P < 0.05$ ). Thus, acacetin significantly inhibited HT-29 cell migration.

### Acacetin induced the apoptosis of HT-29 cells

The effect of acacetin on HT-29 cell apoptosis was further explored using flow cytometry. The results, as depicted in **Figure 11**, demonstrate that the apoptosis rate was significantly different from that in the control group ( $P < 0.01$ ); acacetin significantly induced apoptosis in HT-29 cells. Expression levels of apoptosis-related proteins, including cleaved

Table 3 Top five active ingredients in the herbal ingredient-target-pathway-disease network			
Molecule name	Degree	CC	BC
Acacetin	56	0.433	0.107
Luteolin	54	0.430	0.089
Quercetin	53	0.428	0.090
Bolusanthol B	49	0.419	0.148
Sinoacutine	45	0.414	0.127

CC: Closeness centrality; BC: Betweenness centrality.



**Figure 6 Herbal components-target-pathway-disease network for Herba Patriniae-Coix seed anti-colorectal cancer therapy.** The light-green inverted triangles symbolize herbs, the dark-green circles signify the active ingredients of various herbs, the yellow circles denote general targets, the yellow squares indicate core targets, the orange rectangles correspond to pathways, and the red octagons represent diseases.

caspase-3 and survivin, were quantified *via* western blotting, which revealed that relative to the control group, expression levels of both proteins significantly increased following treatment with acacetin (38  $\mu$ M and 55  $\mu$ M;  $P < 0.05$ ).


**Influence of acacetin on the expression of proteins related to the PI3K/Akt/P53 signaling pathway**

Network pharmacology analysis showed that the mechanism of action of acacetin in CRC likely involves tumor-related signaling pathways, including the PI3K/ Akt pathway. P53, as a vital protein in cell cycle arrest and apoptosis, is a downstream target of the PI3K/ Akt signaling pathway[25]. Consequently, regulation of the PI3K/ Akt signaling pathway by acacetin was investigated. After 48 hours of acacetin treatment in HT-29 cells, the expression levels of *p*-PI3K and *p*-Akt were significantly reduced, whereas a significant increase in p53 protein expression was observed in the experimental group compared to those in the control group ( $P < 0.05$ ) (Figure 12). This indicates that acacetin may regulate the prolifer-

**Table 4** Top five Kyoto Encyclopedia of Genes and Genomes pathways in the herbal ingredient-target-pathway-disease network

KEGG pathway name	Degree	CC	BC
Pathways in cancer	70	0.457	0.163
PI3K-Akt signaling pathway	47	0.404	0.052
Proteoglycans in cancer	34	0.393	0.030
Chemical carcinogenesis-receptor activation	33	0.391	0.038
MicroRNAs in cancer	32	0.388	0.035

CC: Closeness centrality; BC: Betweenness centrality; KEGG: Kyoto Encyclopedia of Genes and Genomes; PI3K: Phosphoinositide 3-kinase.




**Figure 7** Heat map of molecular docking binding energy between the five core components and targets. All five active components showed a strong binding affinity for EGFR, AKT1, TNF, HSP90AA1, and SRC. Among them, acacetin, bolusanthol B, luteolin, and quercetin exhibited the best docking effect with AKT1.

eration and apoptosis of HT-29 cells *via* the PI3K/Akt/P53 signaling pathway, thereby corroborating the network pharmacology findings.

## DISCUSSION

CRC is mainly divided into two types according to its location: Colon cancer, which accounts for 71% of CRC cases, and rectal cancer, which comprises 29% of cases[26]. In 2020, estimates indicated that there were over 1.9 million new cases of CRC globally, resulting in more than 930000 deaths. By 2040, the global incidence of CRC is projected to escalate to 3.2 million new cases annually, representing a 63% increase, with deaths expected to reach 1.6 million per year, representing a 73% increase. The incidence of CRC in adolescents, young adults, and adults is rising annually[27]. In European countries, approximately 11% of CRC cases are attributed to being overweight and obese, particularly due to visceral or abdominal fat. Epidemiological research has indicated that 30%-70% of obese men have an increased risk of CRC. The most prevalent CRC subgroups include the colon, proximal colon, distal colon, and rectum[28]. CRC pathogenesis is influenced by a variety of factors, including poor dietary habits, a sedentary lifestyle, smoking, excessive alcohol intake, obesity, alterations in the gut microbiota, diabetes, and genetic mutations[29,30]. Currently, surgery, radiotherapy, and chemotherapy are the primary treatments for CRC. For patients diagnosed with recurrent and metastatic late-stage CRC, treatment often involves repeated surgery, chemotherapy, radiation therapy, targeted therapy, or a combination thereof [31]. Despite diagnostic and therapeutic advances, the prognosis for patients with CRC remains poor. Furthermore, long-term therapy can result in serious side effects and toxicity, such as nausea, vomiting, mouth ulcers, diarrhea, hepatotoxicity, bone marrow suppression, and immunosuppression, severely limiting their clinical application. Thus, there is an







**Figure 8 Molecular docking results of the core targets.** A: AKT1-Acacetin; B: AKT1-Bolusanthol B; C: AKT1-Luteolin; D: AKT1-Quercetin. The amino acid residues of the human target protein, AKT1, that interacted with luteolin and quercetin were THR-211, TYR-272, and GLN-79, and those that interacted with acacetin and bolusanthol B were THR-211, ASP-274, and THR-81, where the molecules matched well with the protein cavity. In the two-dimensional diagram of molecular interactions, the green dotted lines indicate hydrogen bonding and the red dashed lines indicate hydrophobic interactions, demonstrating directionality.

**Table 5** Top five core targets in the herbal-ingredient-target-pathway-disease network

Target gene	Degree	CC	BC
AR	16	0.452	0.028
CYP19A1	15	0.444	0.030
ESR2	13	0.433	0.019
PIK3R1	12	0.413	0.010
PTPN1	12	0.380	0.011

CC: Closeness centrality; BC: Betweenness centrality.


**Figure 9** Acacetin markedly inhibited HT-29 cell proliferation. A: Cell viability of HT-29 cells measured with the Cell Counting Kit-8 (CCK-8) assay after treatment with different concentrations of acacetin; B: The CCK-8 assay demonstrated that the IC<sub>50</sub> value of HT-29 cells for acacetin was 38 μM. <sup>a</sup>*P* < 0.05 and <sup>b</sup>*P* < 0.001 compared to control cells.**Figure 10** Acacetin suppresses HT-29 cell migration. A: HT-29 cells were treated with various doses of acacetin (0 μM, 38 μM, and 55 μM) for 24 hours and 48 hours, and their migratory behavior analyzed using wound healing assays; B: <sup>a</sup>*P* < 0.05 compared to control cells.

urgent need for alternative treatments that are highly effective and have fewer adverse effects. Modern pharmacological studies and clinical trials have increasingly corroborated the clinical efficacy of Chinese herbal medicines in the prevention and treatment of CRC[32]. TCM has been shown to potentially reduce CRC risk, mitigate chemotherapy-induced adverse reactions[33], and extend the survival rate of patients with advanced CRC[34]. Exploring the molecular mechanisms involved could offer deeper insights into the role of TCM-derived molecules in CRC treatment.



Table 6 Binding energy of the molecular docking					
Target	PDB ID	Ingredient	Binding energy (kcal/mol)	Hydrogen bond number	Action of amino acid residues
AKT1	6HHG	Acacetin	-9.2	1	THR-211
AKT1	6HHG	Bolusanthol B	-10.2	2	ASP-274/THR-81
AKT1	6HHG	Luteolin	-9.5	3	THR-211/TYR-272/GLN-79
AKT1	6HHG	Quercetin	-9.1	3	THR-211/TYR-272/GLN-79


Note: Binding energy function.



**Figure 11 Acacetin promotes apoptosis in HT-29 cells.** A and B: Flow cytometry using Annexin V-FITC staining detected apoptosis in HT-29 cells treated with 38 μM and 55 μM acacetin for 48 hours; C-E: Western blotting analysis evaluating apoptosis in HT-29 cells. The results showed that Acacetin (38 μM, 55 μM) could significantly increase the expression of cleaved caspase-3 protein and inhibited Survivin protein compared with the control group. The histograms indicating statistical significance levels. <sup>a</sup>*P* < 0.05, <sup>b</sup>*P* < 0.01, <sup>c</sup>*P* < 0.001.

Recent studies have demonstrated the pronounced anticancer properties of *Patrinia* and Coix seed, whose extracts have been utilized in pharmacological research targeting various human cancer cell types. Specifically, the ethanol extracts of *Patrinia* yellow flowers and CSO exhibited significant anti-CRC activity in both *in vivo* and *in vitro* studies[35,36]. This study employed network pharmacology and molecular docking for the first time to identify the core components, targets, and potential mechanisms of HC therapy for the treatment of CRC. The anticancer efficacy of the core components of HC was confirmed *in vitro* using the human CRC cell line, HT-29.

The current study identified active HC components *via* the TCMSP, which were further explored using the SwissADME platform. A total of 454 drug targets were identified in the database, and a total of 2685 targets related to CRC were sourced from the GeneCards, DisGeNET, and OMTM databases. Intersecting the targets of the drug ingredients with the CRC targets yielded 171 overlapping targets. After constructing the PPI network, 30 core targets, including *EGFR*, *AKT1*, and *TNF*, among others, were identified, potentially representing the central targets of HC for CRC treatment. GO and KEGG enrichment analyses revealed the involvement of various signaling pathways, notably the PI3K/Akt signaling pathway, proteoglycans in cancer, chemical carcinogen-receptor activation, and microRNAs in



**Figure 12 Acacetin inhibits HT-29 cell progression by targeting the phosphoinositide 3-kinase/Akt/p53 pathway.** Western blotting analysis was conducted on HT-29 cells treated with 38 μM and 55 μM acacetin for 48 hours, with β-actin serving as the internal reference. Data quantification was performed using ImageJ software. Statistical significance was denoted as <sup>a</sup> $P < 0.05$ , <sup>b</sup> $P < 0.01$ , and <sup>c</sup> $P < 0.001$ . PI3K: Phosphoinositide 3-kinase.

cancer. The PI3K/Akt signaling pathway plays a pivotal role in the inhibition of CRC by HC. The PI3K/Akt pathway is implicated in the development of various cancers and influences apoptosis, autophagy, and cell survival[37]. Hyperactivity of the PI3K pathway in numerous cancers leads to reduced apoptosis and persistent proliferation[38]. Numerous oncogenes can activate *PI3K*, and its overexpression serves as a cancer biomarker[39]. Akt functions as a central kinase within the PI3K/Akt signaling pathway, enhancing the cell cycle and influencing numerous cellular functions and processes, including the p53 signaling pathway, cell proliferation, apoptosis, and the cell cycle[40]. The key anti-tumor gene, P53, which is mutated in over 50% of human cancers, loses its anti-tumor activity upon mutation, conferring carcinogenic properties to its protein[41]. Furthermore, numerous studies have indicated a strong relationship between the PI3K/Akt/p53 signaling pathway and cancer development[42], suggesting that inhibition of the PI3K signaling axis represents a promising anticancer treatment approach.

Molecular docking analysis was used to study the mechanism of action of HC on CRC. This technique effectively predicts the binding affinity between TCM components and their targets in accordance with the spatial structures of the ligands and receptors. Among the 10 targets selected for molecular docking analysis, *AKT1* was recognized as a crucial player in cell cycle regulation and PI3K/Akt signaling. Molecular docking analysis revealed that the five active ingredients in HC exhibited strong binding affinities for EGFR, *AKT1*, TNF, HSP90AA1, and SRC. Specifically, acacetin, bolusanthol B, luteolin, and quercetin demonstrated the most effective docking with *AKT1*. HC comprises active ingredients, such as quercetin, luteolin, and sinoacutine; however, these components are commonly found in a variety of herbs, plants, fruits, and vegetables, indicating low specificity. Utilizing Cytoscape 3.9.1, a network incorporating two herbs, 19 active ingredients, 171 intersecting targets, the top 10 pathways, and CRC diseases was constructed to illustrate the herbal-ingredient-target-pathway-disease relationship. Acacetin was identified as having the highest correlation value in this network, and the PI3K/Akt signaling pathway was identified as having the highest degree within the signaling network. Robinin, a dihydroxyl and monomethoxyflavonoid naturally found in plants, such as *Robinia*, *Damiana*, and silver birch, has shown pharmacological potential against cancer cell lines, including chemical prophylaxis and cytotoxicity[43,44]. Studies have demonstrated that acacetin exhibits anticancer properties in the colon cancer cell models, SW480 and PCT-116, by inducing mitochondrial reactive oxygen species and employing an AIF-mediated pathway[45]. Accordingly, acacetin intervention in HT-29 cells was selected to validate the predicted mechanism of action, employing various methods to corroborate the network pharmacology outcomes, such as CCK-8 for cell activity detection, Annexin V-FITC/PI labeling for apoptosis rate measurements, Transwell migration assays, and western blotting analysis. The

CCK-8 assay is frequently used to evaluate the cytotoxic potential of drugs.

This study demonstrated for the first time the cytotoxic effects of a main bioactive component of HC on HT-29 cells after 24 and 48 hours of treatment, causing inhibition of HT-29 cell proliferation. The scratch assay revealed that treatment with 38 and 55  $\mu$ M acacetin significantly inhibited HT-29 cell migration. Annexin V-FITC/PI staining revealed a significant increase in the apoptosis rate of HT-29 cells after acacetin treatment. Furthermore, western blotting analysis revealed that after treatment with 55  $\mu$ M acacetin, the expression level of cleaved caspase-3 significantly increased, whereas that of survivin decreased compared to those in the control group ( $P < 0.05$ ). Caspase enzymes mediate a common pathway in apoptotic signal transduction, with numerous apoptosis-regulating pathways exerting either anti-apoptotic or pro-apoptotic effects through caspase function. Caspase-3 serves as a critical regulatory factor in tumor cell apoptosis[46]. Survivin, a tumor-specific apoptosis suppressor protein, plays a pivotal role in tumor cell differentiation, proliferation, invasion, and metastasis[47]. These findings suggested that acacetin influences HT-29 cell apoptosis by upregulating caspase-3 and downregulating survivin expression.

This study demonstrates that acacetin not only specifically binds to PI3K and Akt, but also influences their phosphorylation levels and *p53* expression. HC treatment increased *p53* expression and decreased PI3K and Akt phosphorylation in HT-29 cells. Inhibition of the PI3K/Akt signaling pathway and upregulation of *p53* exhibit pro-apoptotic effects in CRC cells. Therefore, the PI3K/Akt/*p53* pathway may be the principal mechanism underlying the anti-CRC effects of HC. Akt, a target activated by PI3K, serves as the primary mediator of signal transduction in the PI3K/Akt signaling pathway, and the level of Akt phosphorylation affects cell proliferation and survival[48]. The tumor suppressor gene, *P53*, which is frequently mutated in CRC, has a tumor-suppressive function that is largely attributed to the activation of target genes involved in various processes, such as cell cycle arrest, apoptosis, senescence, autophagy, ferroptosis, and cell metabolism. Hence, inhibition of *p53* activity is crucial for tumorigenesis[49]. CSO, the principal component of Coix seed, has been shown to induce apoptosis in HT-29 cells by modulating the PI3K/Akt signaling pathway[50]. In summary, this study indicates that HC significantly inhibits both the growth and migration of CRC tumor cells *via* the PI3K/Akt/*p53* signaling pathway.

However, this study had some limitations. Owing to the evolving nature and occasional incompleteness of database information, certain bioactive components in HC and their corresponding target proteins might not have been identified in this study. Although this preliminary study identified core targets and signaling pathways of HC for CRC treatment, the specific upstream and downstream regulatory molecules remain undefined. Further investigation into the roles of these pathways in CRC treatment is necessary. In addition, this study only conducted an *in vitro* experimental validation, and future *in vivo* animal studies are needed to further verify and support the role of acacetin in the treatment of CRC. Despite these limitations, this study provides valuable insights and evidence to advance the clinical exploration of HC for CRC treatment.

## CONCLUSION

Utilizing network pharmacology, molecular docking, and *in vitro* validation, this study explored the main active ingredients of HC, as well as their mechanisms of action in treating CRC. The study findings indicate that HC could inhibit colon cancer cell proliferation, impact cell migration, and enhance apoptosis by modulating the PI3K/Akt/*P53* signaling pathway. Overall, this study provides a theoretical foundation for the application of HC in the treatment of CRC.

## FOOTNOTES

**Author contributions:** Li WD was the main contributor to study design and management; Wang CL, Yang BW, and Wang XY conducted the experiments and drafted the manuscript; Chen X, Zhai HY, and Wu Y participated in data collection and figure preparation; Cui MY, Wu JH, Meng QH, and Zhang N participated in discussions and revised the manuscript; and all authors read and approved the final manuscript.

**Supported by** the National Natural Science Foundation of China, No. 82174464; China Academy of Traditional Chinese Medicine Science and Technology Innovation Project, No. CI2021A01806; and Central High Level Traditional Chinese Medicine Hospital Clinical Research and Achievement Transformation Ability Enhancement Project, No. HLCMHPP2023085.

**Conflict-of-interest statement:** Authors have no conflicts of interest to declare.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

**Country of origin:** China

**ORCID number:** Wei-Dong Li 0000-0002-5731-1921.

**S-Editor:** Chen YL

L-Editor: A

P-Editor: Zheng XM

## REFERENCES

- 1 **Bray F**, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2024; **74**: 229-263 [PMID: [38572751](#) DOI: [10.3322/caac.21834](#)]
- 2 **Murphy CC**, Zaki TA. Changing epidemiology of colorectal cancer - birth cohort effects and emerging risk factors. *Nat Rev Gastroenterol Hepatol* 2024; **21**: 25-34 [PMID: [37723270](#) DOI: [10.1038/s41575-023-00841-9](#)]
- 3 **Siegel RL**, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. *CA Cancer J Clin* 2023; **73**: 233-254 [PMID: [36856579](#) DOI: [10.3322/caac.21772](#)]
- 4 **Foda ZH**, Dharwadkar P, Katona BW. Preventive strategies in familial and hereditary colorectal cancer. *Best Pract Res Clin Gastroenterol* 2023; **66**: 101840 [PMID: [37852714](#) DOI: [10.1016/j.bpg.2023.101840](#)]
- 5 **Arif AA**, Chahal D, Ladua GK, Bhang E, Salh B, Rosenfeld G, Loree JM, Donnellan F. Hereditary and Inflammatory Bowel Disease-Related Early Onset Colorectal Cancer Have Unique Characteristics and Clinical Course Compared with Sporadic Disease. *Cancer Epidemiol Biomarkers Prev* 2021; **30**: 1785-1791 [PMID: [34301727](#) DOI: [10.1158/1055-9965.EPI-21-0507](#)]
- 6 **Lewandowska A**, Rudzki G, Lewandowski T, Strykowska-Góra A, Rudzki S. Risk Factors for the Diagnosis of Colorectal Cancer. *Cancer Control* 2022; **29**: 10732748211056692 [PMID: [35000418](#) DOI: [10.1177/10732748211056692](#)]
- 7 **Wei X**, Leng X, Li G, Wang R, Chi L, Sun D. Advances in research on the effectiveness and mechanism of Traditional Chinese Medicine formulas for colitis-associated colorectal cancer. *Front Pharmacol* 2023; **14**: 1120672 [PMID: [36909166](#) DOI: [10.3389/fphar.2023.1120672](#)]
- 8 **Jia R**, Liu N, Cai G, Zhang Y, Xiao H, Zhou L, Ji Q, Zhao L, Zeng P, Liu H, Huo J, Yue X, Zhang Y, Wu C, Sun X, Feng Y, Liu H, Liu H, Han Z, Lai Y, Zhang Y, Han G, Gong H, Wang Y, Li Q. Effect of PRM1201 Combined With Adjuvant Chemotherapy on Preventing Recurrence and Metastasis of Stage III Colon Cancer: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. *Front Oncol* 2021; **11**: 618793 [PMID: [33747930](#) DOI: [10.3389/fonc.2021.618793](#)]
- 9 **Yang YF**, Ge JZ, Wu Y, Xu Y, Liang BY, Luo L, Wu XW, Liu DQ, Zhang X, Song FX, Geng ZY. Cohort study on the effect of a combined treatment of traditional Chinese medicine and Western medicine on the relapse and metastasis of 222 patients with stage II and III colorectal cancer after radical operation. *Chin J Integr Med* 2008; **14**: 251-256 [PMID: [19082795](#) DOI: [10.1007/s11655-008-0251-9](#)]
- 10 **Wang Y**, Liu P, Fang Y, Tian J, Li S, Xu J, Zhao F, Yin X, Zhang Q, Li Y. The Effect of Long-Term Traditional Chinese Medicine Treatment on Survival Time of Colorectal Cancer Based on propensity Score Matching: A Retrospective Cohort Study. *Evid Based Complement Alternat Med* 2020; **2020**: 7023420 [PMID: [32089727](#) DOI: [10.1155/2020/7023420](#)]
- 11 **Li J**, Zhou F, Shang L, Liu N, Liu Y, Zhang M, Wang S, Yang S. Integrated network pharmacology and experimental verification to investigate the mechanisms of YYFZBJS against colorectal cancer via CDK1/PI3K/Akt signaling. *Front Oncol* 2022; **12**: 961653 [PMID: [36457504](#) DOI: [10.3389/fonc.2022.961653](#)]
- 12 **Sui H**, Zhang L, Gu K, Chai N, Ji Q, Zhou L, Wang Y, Ren J, Yang L, Zhang B, Hu J, Li Q. YYFZBJS ameliorates colorectal cancer progression in Apc(Min/+) mice by remodeling gut microbiota and inhibiting regulatory T-cell generation. *Cell Commun Signal* 2020; **18**: 113 [PMID: [32677955](#) DOI: [10.1186/s12964-020-00596-9](#)]
- 13 **Gong L**, Zou W, Zheng K, Shi B, Liu M. The Herba Patriniae (Caprifoliaceae): A review on traditional uses, phytochemistry, pharmacology and quality control. *J Ethnopharmacol* 2021; **265**: 113264 [PMID: [32846192](#) DOI: [10.1016/j.jep.2020.113264](#)]
- 14 **Yang H**, Cheung MK, Yue GG, Leung PC, Wong CK, Lau CB. Integrated Network Pharmacology Analysis and *In Vitro* Validation Revealed the Potential Active Components and Underlying Mechanistic Pathways of Herba Patriniae in Colorectal Cancer. *Molecules* 2021; **26** [PMID: [34641576](#) DOI: [10.3390/molecules26196032](#)]
- 15 **Meng FD**, Yuan L, Lu DD, Yang YT, Xu DJ, Che MY, Nan Y. Anti-tumor effect of coix seed based on the theory of medicinal and food homology. *World J Clin Oncol* 2023; **14**: 593-605 [PMID: [38179404](#) DOI: [10.5306/wjco.v14.i12.593](#)]
- 16 **Lu T**, Yu J, Gao R, Wang J, Wang H, Wang X, Xu B, Cao L, Wu J, Ni B, Li S, Li J. Chinese patent medicine Kanglaite injection for non-small-cell lung cancer: An overview of systematic reviews. *J Ethnopharmacol* 2023; **302**: 115814 [PMID: [36240975](#) DOI: [10.1016/j.jep.2022.115814](#)]
- 17 **Wang X**, Wang ZY, Zheng JH, Li S. TCM network pharmacology: A new trend towards combining computational, experimental and clinical approaches. *Chin J Nat Med* 2021; **19**: 1-11 [PMID: [33516447](#) DOI: [10.1016/S1875-5364\(21\)60001-8](#)]
- 18 **Niu K**, Li Q, Liu Y, Qiao Y, Li B, Wei C, Wang K, Cui L, Zheng C, Wang R, Zhang L, Zhang H, Sun B, Yu B. Molecular Targets and Mechanisms of Scutellariae radix-Coptidis rhizoma Drug Pair for the Treatment of Ulcerative Colitis Based on Network Pharmacology and Molecular Docking. *Evid Based Complement Alternat Med* 2021; **2021**: 9929093 [PMID: [34149863](#) DOI: [10.1155/2021/9929093](#)]
- 19 **Zhang L**, Han L, Wang X, Wei Y, Zheng J, Zhao L, Tong X. Exploring the mechanisms underlying the therapeutic effect of Salvia miltiorrhiza in diabetic nephropathy using network pharmacology and molecular docking. *Biosci Rep* 2021; **41** [PMID: [33634308](#) DOI: [10.1042/BSR20203520](#)]
- 20 **Yang Z**, Lu S, Tang H, Qu J, Wang B, Wang Y, Pan G, Rao B. Molecular Targets and Mechanisms of Hedyotis diffusa-Scutellaria barbata Herb Pair for the Treatment of Colorectal Cancer Based on Network Pharmacology and Molecular Docking. *Evid Based Complement Alternat Med* 2022; **2022**: 6186662 [PMID: [35707465](#) DOI: [10.1155/2022/6186662](#)]
- 21 **Chen L**, Yang A, Li Y, Liu X, Jiang W, Hu K. Molecular mechanism of oroxyli semen against triple-negative breast cancer verified by bioinformatics and *in vitro* experiments. *Medicine (Baltimore)* 2023; **102**: e34835 [PMID: [37713894](#) DOI: [10.1097/MD.00000000000034835](#)]
- 22 **Sun Y**, Jiang P, Yang H, Zhang Z, Zhou Y, Li P, Zeng Q, Zhang X. Network Pharmacology-Based Analysis of the Potential Biological Mechanisms of Coix Seed against Colorectal Cancer. *Evid Based Complement Alternat Med* 2022; **2022**: 9261768 [PMID: [36248436](#) DOI: [10.1155/2022/9261768](#)]
- 23 **Lu S**, Sun X, Zhou Z, Tang H, Xiao R, Lv Q, Wang B, Qu J, Yu J, Sun F, Deng Z, Tian Y, Li C, Yang Z, Yang P, Rao B. Mechanism of Bazhen decoction in the treatment of colorectal cancer based on network pharmacology, molecular docking, and experimental validation. *Front Immunol* 2023; **14**: 1235575 [PMID: [37799727](#) DOI: [10.3389/fimmu.2023.1235575](#)]



- 24 Liu X, Fan Y, Du L, Mei Z, Fu Y. In Silico and In Vivo Studies on the Mechanisms of Chinese Medicine Formula (Gegen Qinlian Decoction) in the Treatment of Ulcerative Colitis. *Front Pharmacol* 2021; **12**: 665102 [PMID: 34177580 DOI: 10.3389/fphar.2021.665102]
- 25 Sabapathy K, Lane DP. Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others. *Nat Rev Clin Oncol* 2018; **15**: 13-30 [PMID: 28948977 DOI: 10.1038/nrclinonc.2017.151]
- 26 Ahmed M. Colon Cancer: A Clinician's Perspective in 2019. *Gastroenterology Res* 2020; **13**: 1-10 [PMID: 32095167 DOI: 10.14740/gr1239]
- 27 Mauri G, Sartore-Bianchi A, Russo AG, Marsoni S, Bardelli A, Siena S. Early-onset colorectal cancer in young individuals. *Mol Oncol* 2019; **13**: 109-131 [PMID: 30520562 DOI: 10.1002/1878-0261.12417]
- 28 Schulpen M, van den Brandt PA. Mediterranean diet adherence and risk of colorectal cancer: the prospective Netherlands Cohort Study. *Eur J Epidemiol* 2020; **35**: 25-35 [PMID: 31494792 DOI: 10.1007/s10654-019-00549-8]
- 29 Simon K. Colorectal cancer development and advances in screening. *Clin Interv Aging* 2016; **11**: 967-976 [PMID: 27486317 DOI: 10.2147/CIA.S109285]
- 30 Kasprzak A, Adamek A. Insulin-Like Growth Factor 2 (IGF2) Signaling in Colorectal Cancer-From Basic Research to Potential Clinical Applications. *Int J Mol Sci* 2019; **20** [PMID: 31623387 DOI: 10.3390/ijms20194915]
- 31 Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. *Gut* 2017; **66**: 683-691 [PMID: 26818619 DOI: 10.1136/gutjnl-2015-310912]
- 32 Salaga M, Zatorski H, Sobczak M, Chen C, Fichna J. Chinese herbal medicines in the treatment of IBD and colorectal cancer: a review. *Curr Treat Options Oncol* 2014; **15**: 405-420 [PMID: 24792017 DOI: 10.1007/s11864-014-0288-2]
- 33 Lv C, Shi C, Li L, Wen X, Xian CJ. Chinese herbal medicines in the prevention and treatment of chemotherapy-induced nausea and vomiting. *Curr Opin Support Palliat Care* 2018; **12**: 174-180 [PMID: 29697417 DOI: 10.1097/SPC.0000000000000348]
- 34 Chen D, Zhao J, Cong W. Chinese Herbal Medicines Facilitate the Control of Chemotherapy-Induced Side Effects in Colorectal Cancer: Progress and Perspective. *Front Pharmacol* 2018; **9**: 1442 [PMID: 30581388 DOI: 10.3389/fphar.2018.01442]
- 35 Zhang M, Sun G, Shen A, Liu L, Ding J, Peng J. *Patrinia scabiosae* folia inhibits the proliferation of colorectal cancer *in vitro* and *in vivo* via G1/S cell cycle arrest. *Oncol Rep* 2015; **33**: 856-860 [PMID: 25500894 DOI: 10.3892/or.2014.3663]
- 36 Qu D, Liu M, Huang M, Wang L, Chen Y, Liu C, Liu Y. Octanoyl galactose ester-modified microemulsion system self-assembled by coix seed components to enhance tumor targeting and hepatoma therapy. *Int J Nanomedicine* 2017; **12**: 2045-2059 [PMID: 28352174 DOI: 10.2147/IJN.S125293]
- 37 Yu L, Wei J, Liu P. Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer. *Semin Cancer Biol* 2022; **85**: 69-94 [PMID: 34175443 DOI: 10.1016/j.semcancer.2021.06.019]
- 38 Polivka J Jr, Janku F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. *Pharmacol Ther* 2014; **142**: 164-175 [PMID: 24333502 DOI: 10.1016/j.pharmthera.2013.12.004]
- 39 Deng S, Leong HC, Datta A, Gopal V, Kumar AP, Yap CT. PI3K/AKT Signaling Tips the Balance of Cytoskeletal Forces for Cancer Progression. *Cancers (Basel)* 2022; **14** [PMID: 35406424 DOI: 10.3390/cancers14071652]
- 40 Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR Signaling in Cancer. *Front Oncol* 2014; **4**: 64 [PMID: 24782981 DOI: 10.3389/fonc.2014.00064]
- 41 Hu J, Cao J, Topatana W, Juengpanich S, Li S, Zhang B, Shen J, Cai L, Cai X, Chen M. Targeting mutant p53 for cancer therapy: direct and indirect strategies. *J Hematol Oncol* 2021; **14**: 157 [PMID: 34583722 DOI: 10.1186/s13045-021-01169-0]
- 42 Chen L, Qing J, Xiao Y, Huang X, Chi Y, Chen Z. TIM-1 promotes proliferation and metastasis, and inhibits apoptosis, in cervical cancer through the PI3K/AKT/p53 pathway. *BMC Cancer* 2022; **22**: 370 [PMID: 35392845 DOI: 10.1186/s12885-022-09386-7]
- 43 Singh S, Gupta P, Meena A, Luqman S. Acacetin, a flavone with diverse therapeutic potential in cancer, inflammation, infections and other metabolic disorders. *Food Chem Toxicol* 2020; **145**: 111708 [PMID: 32866514 DOI: 10.1016/j.fct.2020.111708]
- 44 Aslan BT, Ertugrul B, Iplik ES, Cakmakoglu B. Apoptotic effects of acacetin in human colon cancer HT-29 and HCT 116 cells. *J Cancer Res Ther* 2021; **17**: 1479-1482 [PMID: 34916381 DOI: 10.4103/jcrt.JCRT\_1097\_19]
- 45 Prasad N, Sharma JR, Yadav UCS. Induction of growth cessation by acacetin *via*  $\beta$ -catenin pathway and apoptosis by apoptosis inducing factor activation in colorectal carcinoma cells. *Mol Biol Rep* 2020; **47**: 987-1001 [PMID: 31734898 DOI: 10.1007/s11033-019-05191-x]
- 46 Asadi M, Taghizadeh S, Kaviani E, Vakili O, Taheri-Anganeh M, Tahamtan M, Savardashtaki A. Caspase-3: Structure, function, and biotechnological aspects. *Biotechnol Appl Biochem* 2022; **69**: 1633-1645 [PMID: 34342377 DOI: 10.1002/bab.2233]
- 47 Kondapuram SK, Ramachandran HK, Arya H, Coumar MS. Targeting survivin for cancer therapy: Strategies, small molecule inhibitors and vaccine based therapeutics in development. *Life Sci* 2023; **335**: 122260 [PMID: 37963509 DOI: 10.1016/j.lfs.2023.122260]
- 48 Stefani C, Miricescu D, Stanescu-Spinu II, Nica RI, Greabu M, Totan AR, Jinga M. Growth Factors, PI3K/AKT/mTOR and MAPK Signaling Pathways in Colorectal Cancer Pathogenesis: Where Are We Now? *Int J Mol Sci* 2021; **22** [PMID: 34638601 DOI: 10.3390/ijms221910260]
- 49 Liebl MC, Hofmann TG. The Role of p53 Signaling in Colorectal Cancer. *Cancers (Basel)* 2021; **13** [PMID: 33924934 DOI: 10.3390/cancers13092125]
- 50 Ni C, Li B, Ding Y, Wu Y, Wang Q, Wang J, Cheng J. Anti-Cancer Properties of Coix Seed Oil against HT-29 Colon Cells through Regulation of the PI3K/AKT Signaling Pathway. *Foods* 2021; **10** [PMID: 34829119 DOI: 10.3390/foods10112833]



Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** [office@baishideng.com](mailto:office@baishideng.com)

**Help Desk:** <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

